Eris Lifesciences Financial Results
- Market cap
- ₹15,937 crore
- P/E
- 24.8
- P/B
- 4.08
- ROE
- 18.3%
- Dividend yield
- 1.20%
For the year ended Mar 2019, Eris Lifesciences reported revenue of ₹982 crore and net profit of ₹291 crore, against ₹1,074 crore and ₹297 crore a year earlier.
Eris Lifesciences annual profit and loss
Financial years, newest first. TTM = trailing twelve months.
| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 982 | 1,074 | 1,212 | 1,347 | 1,662 | 1,991 | 2,879 | 3,115 | 3,212 |
| Expenses | 637 | 706 | 781 | 862 | 1,123 | 1,313 | 1,861 | 1,994 | 2,073 |
| Operating profit | 345 | 368 | 431 | 485 | 539 | 678 | 1,019 | 1,121 | 1,140 |
| Operating margin % | 35% | 34% | 36% | 36% | 32% | 34% | 35% | 36% | 35% |
| Other income | 32 | 15 | 9 | 26 | 9 | 21 | 17 | -10 | -11 |
| Interest | 23 | 2 | 2 | 4 | 26 | 85 | 231 | 193 | 191 |
| Depreciation | 36 | 50 | 43 | 65 | 117 | 183 | 315 | 279 | 281 |
| Profit before tax | 317 | 331 | 394 | 442 | 405 | 431 | 489 | 639 | 657 |
| Tax % | 8% | 11% | 10% | 8% | 8% | 8% | 23% | -1% | -1% |
| Net profit | 291 | 297 | 355 | 406 | 374 | 397 | 375 | 648 | 666 |
| EPS (₹) | 21.38 | 21.80 | 26.11 | 29.86 | 28.10 | 28.82 | 25.84 | 44.72 | 46.48 |
| Dividend payout % | — | — | — | — | — | — | — | — | — |
Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.
Eris Lifesciences financial results — frequently asked questions
What is Eris Lifesciences' annual revenue and net profit?
For the financial year ended Mar 2019, Eris Lifesciences' revenue was ₹982 crore and net profit ₹291 crore; net profit fell 2.02% from ₹297 crore in Mar 2020.
How fast has Eris Lifesciences grown over three years?
From Mar 2022 to Mar 2019, Eris Lifesciences' revenue grew at a compound annual rate of -10.0% and net profit at -10.5%. Past growth does not indicate future results.
What is the EPS of Eris Lifesciences?
Annual EPS for Mar 2019 was ₹21.38.
Are these figures consolidated or standalone?
They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.
Same Data For Peers
Trade Eris Lifesciences With ATS
Track ERIS live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.